515 related articles for article (PubMed ID: 9546426)
21. Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells.
Mincione G; Piccirelli A; Lazzereschi D; Salomon DS; Colletta G
J Cell Physiol; 1998 Aug; 176(2):383-91. PubMed ID: 9648926
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
23. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
25. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha.
Ethier SP; Langton BC; Dilts CA
Mol Carcinog; 1996 Feb; 15(2):134-43. PubMed ID: 8599580
[TBL] [Abstract][Full Text] [Related]
26. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
Liu SM; Carpenter G
J Cell Physiol; 1993 Nov; 157(2):237-42. PubMed ID: 7901224
[TBL] [Abstract][Full Text] [Related]
27. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M
Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890
[TBL] [Abstract][Full Text] [Related]
28. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
Ram TG; Kokeny KE; Dilts CA; Ethier SP
J Cell Physiol; 1995 Jun; 163(3):589-96. PubMed ID: 7775601
[TBL] [Abstract][Full Text] [Related]
29. Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock.
King CR; Borrello I; Porter L; Comoglio P; Schlessinger J
Oncogene; 1989 Jan; 4(1):13-8. PubMed ID: 2464783
[TBL] [Abstract][Full Text] [Related]
30. Heregulin-dependent translocation and hyperphosphorylation of ErbB-2.
Zhou W; Carpenter G
Oncogene; 2001 Jun; 20(29):3918-20. PubMed ID: 11439355
[TBL] [Abstract][Full Text] [Related]
31. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
Daly JM; Jannot CB; Beerli RR; Graus-Porta D; Maurer FG; Hynes NE
Cancer Res; 1997 Sep; 57(17):3804-11. PubMed ID: 9288791
[TBL] [Abstract][Full Text] [Related]
32. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
33. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
34. Type I growth factor receptors: current status and future work.
Gullick WJ
Biochem Soc Symp; 1998; 63():193-8. PubMed ID: 9513723
[TBL] [Abstract][Full Text] [Related]
35. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
Schaefer G; Fitzpatrick VD; Sliwkowski MX
Oncogene; 1997 Sep; 15(12):1385-94. PubMed ID: 9333014
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
Simpson BJ; Bartlett JM; Macleod KG; Rabiasz G; Miller EP; Rae AL; Gordge P; Leake RE; Miller WR; Smyth J; Langdon SP
Br J Cancer; 1999 Mar; 79(7-8):1098-103. PubMed ID: 10098742
[TBL] [Abstract][Full Text] [Related]
37. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies to the EGF receptor act as betacellulin antagonists.
Modjtahedi H; Dean C
Biochem Biophys Res Commun; 1996 Apr; 221(3):625-30. PubMed ID: 8630011
[TBL] [Abstract][Full Text] [Related]
39. Differential distributions of peptides in the epidermal growth factor family and phosphorylation of ErbB 1 receptor in adult rat brain.
Piao YS; Iwakura Y; Takei N; Nawa H
Neurosci Lett; 2005 Dec; 390(1):21-4. PubMed ID: 16129559
[TBL] [Abstract][Full Text] [Related]
40. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
